journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/29160739/neural-correlates-of-effort-dependent-and-effort-independent-cognitive-fatigue-components-in-patients-with-multiple-sclerosis
#1
Stefan Spiteri, Thomas Hassa, Dolores Claros-Salinas, Christian Dettmers, Mircea Ariel Schoenfeld
BACKGROUND: Among patients with multiple sclerosis (MS), fatigue is the most commonly reported symptom. It can be subdivided into an effort-dependent (fatigability) and an effort-independent component (trait-fatigue). OBJECTIVE: The objective was to disentangle activity changes associated with effort-independent "trait-fatigue" from those associated with effort-dependent fatigability in MS patients. METHODS: This study employed behavioral measures and functional magnetic imaging to investigate neural changes in MS patients associated with fatigue...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29154723/evaluating-rehabilitation-an-ongoing-challenge
#2
Jennifer Freeman
No abstract text is available yet for this article.
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29154721/validating-the-use-of-brain-volume-cutoffs-to-identify-clinically-relevant-atrophy-in-rrms
#3
Francesca Bovis, Nicola De Stefano, Joshua R Steinerman, Volker Knappertz, Maria Pia Sormani
BACKGROUND: Baseline brain volume (BV) is predictive at a group level but is difficult to interpret at the single patient level. OBJECTIVE: To validate BV cutoffs able to identify clinically relevant atrophy in relapsing-remitting multiple sclerosis (RRMS) patients. METHODS: The expected normalized brain volume (NBV) for each patient was calculated using RRMS patients from two phase III clinical trials, applying a linear formula developed on the baseline variable of an independent data set...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29143562/pathological-cut-offs-of-global-and-regional-brain-volume-loss-in-multiple-sclerosis
#4
Tomas Uher, Manuela Vaneckova, Jan Krasensky, Lukas Sobisek, Michaela Tyblova, Jana Volna, Zdenek Seidl, Niels Bergsland, Michael G Dwyer, Robert Zivadinov, Nicola De Stefano, Maria Pia Sormani, Eva Kubala Havrdova, Dana Horakova
BACKGROUND: Volumetric MRI surrogate markers of disease progression are lacking. OBJECTIVE: To establish cut-off values of brain volume loss able to discriminate between healthy controls and MS patients. METHODS: In total, 386 patients after first demyelinating event suggestive of MS (CIS), 964 relapsing-remitting MS (RRMS) patients, 63 secondary-progressive MS (SPMS) patients and 58 healthy controls were included in this longitudinal study...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29143553/cognitive-function-is-a-major-determinant-of-income-among-multiple-sclerosis-patients-in-sweden-acting-independently-from-physical-disability
#5
Andrius Kavaliunas, Virginija Danylaite Karrenbauer, Hanna Gyllensten, Ali Manouchehrinia, Anna Glaser, Tomas Olsson, Kristina Alexanderson, Jan Hillert
BACKGROUND: In multiple sclerosis (MS), various aspects of cognitive function can be detrimentally affected, thus patients' employment and social functioning is commonly impacted. OBJECTIVE: To analyse income among MS patients in relation to cognitive function, assessed with the Symbol Digit Modalities Test (SDMT). METHODS: A cross-sectional study including 2080 MS patients was conducted linking national register-based data. Descriptive statistics and a two-part model were used to estimate differences in earnings and social benefits...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29143550/safety-and-tolerability-of-inebilizumab-medi-551-an-anti-cd19-monoclonal-antibody-in-patients-with-relapsing-forms-of-multiple-sclerosis-results-from-a-phase-1-randomised-placebo-controlled-escalating-intravenous-and-subcutaneous-dose-study
#6
Mark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, Andrzej Potemkowski, Jing Li, Kaushik Patra, Jacob Wesley, Soraya Madani, Gerard Barron, Eliezer Katz, Armando Flor
BACKGROUND: B cells may be involved in the pathophysiology of multiple sclerosis (MS). Inebilizumab (formerly MEDI-551) binds to and depletes CD19(+) B cells. OBJECTIVES: To assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of inebilizumab in adults with relapsing MS. METHODS: This phase 1 trial randomised 28 patients 3:1 (21, inebilizumab; 7, placebo) to inebilizumab (2 intravenous (IV) doses, days 1 and 15: 30, 100 or 600 mg; or single subcutaneous (SC) dose on day 1: 60 or 300 mg) or matching placebo, with follow-up until at least week 24 or return of CD19(+) B-cell count to ⩾80 cells/µL...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29125439/intense-immunosuppression-followed-by-autologous-haematopoietic-stem-cell-transplantation-as-a-therapeutic-strategy-in-aggressive-forms-of-multiple-sclerosis
#7
Gianluigi Mancardi, Maria Pia Sormani, Paolo A Muraro, Giacomo Boffa, Riccardo Saccardi
In the majority of relapsing multiple sclerosis patients, the disease can be quite easily controlled by already available, approved therapies. There are, however, some aggressive cases who continue to have clinical and magnetic resonance imaging (MRI) activity in spite of the treatment. These are the cases who may now receive benefit from intense immunosuppression followed by autologous haematopoietic stem cell transplantation (aHSCT). In this review, we describe the method and the rationale of aHSCT, the more recently published studies that demonstrate its efficacy in selected multiple sclerosis cases, the problems related to safety and the transplant-related mortality risk of the procedure...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29125422/characteristics-of-morphologic-macular-abnormalities-in-neuroimmunology-practice
#8
Omar Al-Louzi, Elias S Sotirchos, Angela Vidal-Jordana, Shin C Beh, Julia Button, Howard S Ying, Laura J Balcer, Elliot M Frohman, Shiv Saidha, Peter A Calabresi, Scott D Newsome
BACKGROUND: Morphologic macular abnormalities (MMAs) are frequently seen on macular optical coherence tomography (OCT) imaging in neuroimmunology practice, yet studies pragmatically assessing prevalence and risk factors of MMAs to date are limited. OBJECTIVE: To describe the characteristics of MMAs in a neuroimmunology-based academic practice. METHODS: Cross-sectional study of 1450 patients (2900 eyes) who underwent spectral-domain macular OCT between June 2010 and June 2012...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29125019/the-loss-of-macular-ganglion-cells-begins-from-the-early-stages-of-disease-and-correlates-with-brain-atrophy-in-multiple-sclerosis-patients
#9
Anna M Pietroboni, Laura Dell'Arti, Michela Caprioli, Marta Scarioni, Tiziana Carandini, Andrea Arighi, Laura Ghezzi, Giorgio G Fumagalli, Milena A De Riz, Paola Basilico, Annalisa Colombi, Eleonora Benatti, Fabio Triulzi, Elio Scarpini, Francesco Viola, Daniela Galimberti
BACKGROUND: The importance of neurodegeneration in multiple sclerosis (MS) is increasingly well recognized. OBJECTIVES: To evaluate retinal pathology using optical coherence tomography (OCT) and to investigate possible associations between retinal layers' thickness and specific patterns of gray matter volume in patients with a new diagnosis of MS. METHODS: A total of 31 patients underwent OCT scans and brain magnetic resonance imaging. In total, 30 controls underwent the same OCT procedure...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29117789/nlrp3-polymorphisms-and-response-to-interferon-beta-in-multiple-sclerosis-patients
#10
Sunny Malhotra, Melissa Sorosina, Jordi Río, Silvia Peroni, Luciana Midaglia, Luisa M Villar, José C Álvarez-Cermeño, Ina Schroeder, Federica Esposito, Ferdinando Clarelli, Uwe K Zettl, Jeannette Lechner-Scott, Nino Spataro, Arcadi Navarro, Giancarlo Comi, Xavier Montalban, Filippo Martinelli-Boneschi, Manuel Comabella
We aimed to investigate whether NLR family, pyrin domain containing 3 (NLRP3) polymorphisms are associated with the response to interferon-beta (IFNβ) in multiple sclerosis (MS) patients. A total of 14 NLRP3 polymorphisms were genotyped in a cohort of 665 relapsing-remitting MS patients recruited across 5 centers and classified into responders and non-responders according to clinical-radiological criteria after 1 year of IFNβ treatment. A meta-analysis failed to demonstrate significant associations between the response to IFNβ and NLRP3 polymorphisms...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29117778/serotonin-a-mediator-of-the-gut-brain-axis-in-multiple-sclerosis
#11
Tsveta S Malinova, Christine D Dijkstra, Helga E de Vries
BACKGROUND: The significance of the gut microbiome for the pathogenesis of multiple sclerosis (MS) has been established, although the underlying signaling mechanisms of this interaction have not been sufficiently explored. OBJECTIVES: We address this point and use serotonin (5-hydroxytryptamine (5-HT))-a microbial-modulated neurotransmitter (NT) as a showcase to demonstrate that NTs regulated by the gut microbiome are potent candidates for mediators of the gut-brain axis in demyelinating disorders...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29113572/effects-of-an-individual-12-week-community-located-start-to-run-program-on-physical-capacity-walking-fatigue-cognitive-function-brain-volumes-and-structures-in-persons-with-multiple-sclerosis
#12
Peter Feys, Lousin Moumdjian, Florian Van Halewyck, Inez Wens, Bert O Eijnde, Bart Van Wijmeersch, Veronica Popescu, Paul Van Asch
BACKGROUND: Exercise therapy studies in persons with multiple sclerosis (pwMS) primarily focused on motor outcomes in mid disease stage, while cognitive function and neural correlates were only limitedly addressed. OBJECTIVES: This pragmatic randomized controlled study investigated the effects of a remotely supervised community-located "start-to-run" program on physical and cognitive function, fatigue, quality of life, brain volume, and connectivity. METHOD: In all, 42 pwMS were randomized to either experimental (EXP) or waiting list control (WLC) group...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29111883/multiple-sclerosis-and-hla-genotypes-a-possible-influence-on-brain-atrophy
#13
Lorena Lorefice, Giuseppe Fenu, Claudia Sardu, Jessica Frau, Giancarlo Coghe, Gianna Costa, Lucia Schirru, Maria Antonietta Secci, Vincenzo Sechi, Maria Antonietta Barracciu, Maria Giovanna Marrosu, Eleonora Cocco
BACKGROUND: The strongest genetic determinant for multiple sclerosis (MS) is located at the human leukocyte antigen (HLA) class II DRB1 and DQB1 loci. OBJECTIVES: To investigate the possible role of predisposing HLA genotypes in determining brain atrophy. METHODS: HLA genotypes were categorized as high risk (two predisposing haplotypes) or medium/low risk (one or no predisposing haplotypes). Patients underwent a brain magnetic resonance imaging (MRI) study and volumes of white matter (WM), gray matter (GM), and whole brain (WB) were estimated with SIENAX...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29111873/longitudinal-optical-coherence-tomography-study-of-optic-atrophy-in-secondary-progressive-multiple-sclerosis-results-from-a-clinical-trial-cohort
#14
Kimberly M Winges, Charles F Murchison, Dennis N Bourdette, Rebecca I Spain
BACKGROUND: Limited prospective information exists regarding spectral-domain optical coherence tomography (SD-OCT) in secondary progressive multiple sclerosis (SPMS). OBJECTIVE: Document cross-sectional and longitudinal retinal nerve fiber layer (RNFL) and macular ganglion cell plus inner plexiform layer (GCIPL) features of an SPMS clinical trial cohort. METHODS: Prospective, observational study using a 2-year randomized placebo-controlled SPMS trial cohort with yearly SD-OCT testing...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29106333/monomethyl-fumarate-treatment-impairs-maturation-of-human-myeloid-dendritic-cells-and-their-ability-to-activate-t-cells
#15
Maria Antonietta Mazzola, Radhika Raheja, Keren Regev, Vanessa Beynon, Felipe von Glehn, Anu Paul, Isabelle Pierre, Pia Kivisakk, Howard L Weiner, Roopali Gandhi
BACKGROUND: Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) effectively lead to reduction in disease relapses and active magnetic resonance imaging (MRI) lesions. DMF and MMF are known to be effective in modulating T- and B-cell responses; however, their effect on the phenotype and function of human myeloid dendritic cells (mDCs) is not fully understood. OBJECTIVE: To investigate the role of MMF on human mDCs maturation and function. METHODS: mDCs from healthy controls were isolated and cultured in vitro with MMF...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29095099/an-overview-of-biosimilars-and-non-biologic-complex-drugs-in-europe-the-united-states-and-canada-and-their-relevance-to-multiple-sclerosis
#16
Sophia Gran-Ruaz, Arvind Mani, Sherry O'Quinn
The advent of biological medicines has significantly transformed the landscapes of many disease spaces and improved the lives of millions around the world. However, the structural complexity and sensitivity of such products result in a high price tag, adding to already financially strained healthcare systems. As these and other expensive complex drugs lose market exclusivity, stakeholders eagerly await the arrival of lower cost alternatives, such as biosimilars and subsequent entry non-biological complex drugs (NBCDs)...
November 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29106329/the-naims-cooperative-pilot-project-design-implementation-and-future-directions
#17
Jiwon Oh, Rohit Bakshi, Peter A Calabresi, Ciprian Crainiceanu, Roland G Henry, Govind Nair, Nico Papinutto, R Todd Constable, Daniel S Reich, Daniel Pelletier, William Rooney, Daniel Schwartz, Ian Tagge, Russell T Shinohara, Jack H Simon, Nancy L Sicotte
The North American Imaging in Multiple Sclerosis (NAIMS) Cooperative represents a network of 27 academic centers focused on accelerating the pace of magnetic resonance imaging (MRI) research in multiple sclerosis (MS) through idea exchange and collaboration. Recently, NAIMS completed its first project evaluating the feasibility of implementation and reproducibility of quantitative MRI measures derived from scanning a single MS patient using a high-resolution 3T protocol at seven sites. The results showed the feasibility of utilizing advanced quantitative MRI measures in multicenter studies and demonstrated the importance of careful standardization of scanning protocols, central image processing, and strategies to account for inter-site variability...
October 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29106327/asymptomatic-spinal-cord-lesions-do-not-predict-the-time-to-disability-in-patients-with-early-multiple-sclerosis
#18
Iris Dekker, Madeleine H Sombekke, Birgit I Witte, Jeroen Jg Geurts, Frederik Barkhof, Bernard Mj Uitdehaag, Joep Killestein, Mike P Wattjes
BACKGROUND: The presence of asymptomatic spinal cord (SC) lesions in patients with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) predicts conversion to clinically definite multiple sclerosis (CDMS). The relation between asymptomatic SC abnormalities and disability progression warrants further investigation. OBJECTIVE: To determine the prognostic value of asymptomatic SC lesions in CIS and early RRMS with respect to the time to disability development...
October 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29095097/peripapillary-retinal-nerve-fibre-layer-as-measured-by-optical-coherence-tomography-is-a-prognostic-biomarker-not-only-for-physical-but-also-for-cognitive-disability-progression-in-multiple-sclerosis
#19
Gabriel Bsteh, Harald Hegen, Barbara Teuchner, Matthias Amprosi, Klaus Berek, Felix Ladstätter, Sebastian Wurth, Michael Auer, Franziska Di Pauli, Florian Deisenhammer, Thomas Berger
BACKGROUND: Peripapillary retinal nerve fibre layer (pRNFL) thickness is emerging as a marker of axonal degeneration in multiple sclerosis (MS). OBJECTIVE: We aimed to prospectively assess the predictive value of pRNFL for progression of physical and cognitive disability in relapsing-remitting MS (RRMS). METHODS: In this 3-year longitudinal study on 151 RRMS patients, pRNFL was measured by spectral-domain optical coherence tomography (OCT)...
October 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29076770/corrigendum
#20
(no author information available yet)
Pietroboni A, Arighi A, De Riz M, Scarpini E, Galimberti D, Bresolin N and Rango M. Brain temperature in multiple sclerosis. Mult Scler 2014; 20: 894-896. DOI: 10.1177/1352458513508838 In this article, the third author's name was misspelled in the online and print versions. It should have appeared as Milena De Riz. The authors' apologies for any confusion.
October 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"